Though the stage is apparently set for Bristol’s contingent value right to pay out, the instrument trades at depressed levels.
The US regulator granted 14 accelerated approvals in 2019, fewer than in the previous two years, and the sector remains slow at conversions.
Vertex is due the first pivotal data on its cystic fibrosis triplets, while Global Blood Therapeutics will soon find out whether it can take a shortcut on voxelotor’s…
Analysis of me-too drug approvals over time shows trends across therapy areas.
The companies hope that the US regulator approves patisiran and lorlatinib.
A new influenza antiviral from Roche and Shionogi could become an important new medicine for both groups, if payers can be convinced.